

CENTRUS ENERGY CORP.

NYSE: LEU

America's Only NRC-Approved HALEU Producer

Fueling the Advanced Nuclear Renaissance

\$282

Price Target

37.5% Upside

\$3.8B

Total Backlog

To 2040

\$449M

2025 Revenue

+40% YoY

\$2.0B

Cash & Sec.

Balance Sheet

Company Overview

Who Is Centrus Energy?

- Nuclear fuel supplier focused on uranium enrichment & technical services
- World's most diversified supplier of enriched uranium for civilian nuclear power
- Deploying advanced centrifuge technology to produce HALEU for next-gen SMRs
- Only NRC-approved HALEU producer in the U.S.

LEU Segment

77% of 2025 Revenue (\$346M)

- Sells SWUs & uranium to nuclear utilities
- \$2.3B contingent backlog
- Clients: U.S., Belgium, Japan, Netherlands & more

Technical Solutions Segment

23% of 2025 Revenue (~\$102M)

- DOE HALEU Operations Contract (cost-plus)
- Only facility actively enriching HALEU in the U.S.
- Piketon, OH centrifuge facility

Investment Thesis

01

Regulatory Moat — Only NRC-Approved HALEU Producer

Centrus is the only company approved by the U.S. Nuclear Regulatory Commission to produce HALEU. Since ~two-thirds of Small Modular Reactors require HALEU, Centrus sits directly in the path of surging next-generation reactor demand.

02

AI-Driven Energy Demand Creates Structural Tailwind

Energy consumption is set to increase exponentially as AI drives demand for 24/7 carbon-free baseload power. Nuclear — and specifically advanced reactors requiring HALEU — is the only scalable answer, positioning Centrus as a critical infrastructure play.

03

Geopolitical Advantage — Russian Decoupling

The U.S. is moving decisively away from Russian uranium. This makes Centrus the primary beneficiary of federal subsidies and domestic supply chain mandates. A geopolitical risk for the broader market becomes a direct competitive advantage.

Industry Overview

The uranium enrichment industry is a key part of nuclear energy, providing ~9–10% of the world's electricity. Natural uranium contains only 0.7% U-235, but reactors need 3–5%, requiring a costly, tightly-regulated enrichment process.

Global Oligopoly

Only Rosatom, Urenco, and Orano supply most of the world's enrichment. This concentrated structure raises energy-security concerns and accelerates country-level reshoring efforts, directly benefiting Centrus.

Steady + Growing Demand

Nuclear plants sign long-term SWU contracts. With more reactors under construction and nuclear capacity projected to rise through 2050, demand is structurally growing.

Market Size & Growth

The enrichment market was worth \$14–15B in 2025 and is projected to grow to over \$22B by 2030 as advanced reactors and SMRs come online globally — a 47% increase in 5 years.

Uranium Enrichment Market Size

2025 \$14–15B

2030E \$22B+ (+47%)

Catalyst Path

By 2029

Centrifuge Enrichment Facility

Construction at Piketon, OH reduces reliance on foreign enrichment, strengthens domestic supply chain, and unlocks the full \$2.3B contingent LEU backlog.

8-Year Extension

HALEU Contract Extension

Extension of its HALEU Operations Contract for up to eight years provides long-duration revenue visibility. Cost-plus structure protects margins through expansion.

Near-Term

NNSA Sole-Source Award (~\$900M)

As the only production-ready HALEU supplier for the NNSA, Centrus holds a strategic advantage that could lead to a sole-source contract worth ~\$900M.

2026–2028

DOE Task Order Awards (~\$1.8B)

DOE task orders for LEU (~\$900M) and HALEU (~\$900M) are pending. Awards would de-risk the expansion and serve as a major re-rating catalyst.

Key Risks

Demand Volatility

If AI demand cools, the HALEU market may not materialize as quickly as projected. Nuclear energy's long development timelines amplify this risk — commitments made today won't generate revenue for years.

Nuclear Waste Management

Persistent logistical and financial challenges of nuclear waste management continue to threaten the long-term feasibility of nuclear as a primary energy solution and could dampen public and regulatory support.

Execution & Supply Gap Risk

Centrus is navigating a high-stakes decoupling from Russian supply chains before domestic manufacturing is fully established. This transition requires massive CapEx and carries a high probability of cost overruns.

Revenue Concentration

Revenue is heavily concentrated among a few large utility companies. Any shift in procurement strategies or failure to execute large-scale projects could result in significant financial downturns.

Valuation

Intrinsic Value: DCF Analysis

- ▶ Current price: ~\$205/share (at time of analysis)
- ▶ 2026E Revenue: \$450M → P/S of 9.1x at current price
- ▶ WACC: 9% | Terminal EBITDA Margin: 34%
- ▶ Sole domestic HALEU moat reflected in terminal value
- ▶ \$3.8B backlog provides base-case downside protection
- ▶ Revenue re-acceleration to 15% CAGR by 2028 as HALEU scales
- ▶ Comparable re-rating: 12.5x 2026 Sales = \$282 target

Price Target

\$282

per share • Upside: 37.5%

Bear Case

\$120–\$140

DOE delayed; AI demand disappoints; HALEU market fails to materialize

Base Case

\$282

DOE confirmed; HALEU ramp on schedule; 15% revenue CAGR by 2028

Bull Case

\$380–\$450

NNSA sole-source + both DOE task orders; HALEU exceeds projections

Financial Snapshot

\$448.7M

2025 Revenue

\$117.5M

Gross Profit

\$77.8M

Net Income

17.3%

Net Margin


\$2.0B

Cash & Securities

\$3.8B

Total Backlog

Annual Revenue (\$M)



Source: SEC filings, FactSet. 2026E based on analyst consensus (~\$490M, 7% CAGR).

Investment Recommendation

BUY | NYSE: LEU | Price Target: \$282

✓ Only NRC-approved HALEU producer — regulatory moat with no domestic challenger

✓ AI + electrification create a multi-decade structural tailwind for nuclear energy

✓ Russian uranium decoupling transforms a geopolitical risk into a competitive advantage

✓ Four independent catalysts (centrifuge facility, contract extension, DOE awards, NNSA) not yet fully priced in

Questions?

CENTRUS ENERGY CORP. | NYSE: LEU

This presentation was prepared for educational and investment club purposes only and does not constitute investment advice.